Compare stocks

Almirall, S.A. is a pharmaceutical company headquartered in Barcelona, Spain. It specializes in the development and commercialization of proprietary medicines, with a focus on dermatology and other specialist-driven therapeutic areas. Almirall's notable products target conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1943, the company has expanded its geographical footprint across Europe and North America through strategic acquisitions and partnerships. Almirall emphasizes research and development, maintaining a pipeline of innovative treatments aimed at unmet medical needs. Its strategic positioning is reinforced by collaborations with healthcare professionals and institutions to enhance patient care.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.